Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 2Meningeal Carcinomatosis 1Glioblastoma 1

Interventions

Pemetrexed 5Bevacizumab 5osimertinib 3aflutinib 3Temozolomide 3trastuzumab deruxtecan 2Topotecan 2Spinal Puncture 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Methotrexate 2Magnetic Resonance Spectroscopy 2tucatinib 1trioctyl phosphine oxide 1pembrolizumab 1nimotuzumab 1merphos 1lenvatinib 1glutathione pegylated liposomal doxorubicin 1epothilone B 1envafolimab 1camrelizumab 1XL647 1Trastuzumab 1Transplantation, Autologous 1Radiotherapy 1Radiosurgery 1Nivolumab 1Mental Status and Dementia Tests 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Meningeal Carcinomatosis × XL647 × Clear all
NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡